MCID: HMT002
MIFTS: 64

Hematologic Cancer malady

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Hematologic Cancer

Aliases & Descriptions for Hematologic Cancer:

Name: Hematologic Cancer 38 12 52 14
Hematologic Neoplasms 42 69
Hematologic Neoplasm 12 29
Hematopoietic and Lymphoid System Tumor 12
Malignant Hematopoietic Neoplasm 12
Hematologic Malignancies 52
Hematopoietic Neoplasms 69
Hematologic Malignancy 12
Hematopoietic Neoplasm 12
Hematological Tumors 12
Hematopoietic Cancer 12
Hematopoietic Tumors 12
Blood Cancer 12
Liquid Tumor 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2531
MeSH 42 D019337
NCIt 47 C27134
SNOMED-CT 64 414388001 414644002
UMLS 69 C0376544

Summaries for Hematologic Cancer

Disease Ontology : 12 An immune system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.

MalaCards based summary : Hematologic Cancer, also known as hematologic neoplasms, is related to myeloproliferative neoplasm and refractory hematologic cancer. An important gene associated with Hematologic Cancer is RUNX1 (Runt Related Transcription Factor 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Pathways in cancer. The drugs Adcetris and Arranon have been mentioned in the context of this disorder. Affiliated tissues include bone, lymph node and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and hematopoietic system

Related Diseases for Hematologic Cancer

Diseases related to Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
id Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 31.4 CSF3 JAK2 RUNX1
2 refractory hematologic cancer 12.1
3 central nervous system hematologic cancer 12.1
4 platelet disorder, familial, with associated myeloid malignancy 11.0
5 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.9
6 bone marrow cancer 10.7
7 lymphoma 10.7
8 central nervous system leukemia 10.7
9 acquired pure red cell aplasia 10.7
10 pulmonary alveolar proteinosis, acquired 10.7
11 central nervous system lymphoma 10.7
12 mast cell neoplasm 10.7
13 histiocytic and dendritic cell cancer 10.7
14 refractory hairy cell leukemia 10.7
15 monoclonal gammopathy of uncertain significance 10.5
16 lymphoma, non-hodgkin 10.5
17 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.5
18 bone marrow necrosis 10.5
19 temporal arteritis 10.5
20 8p11 myeloproliferative syndrome 10.5
21 vasculitis syndromes of the central and peripheral nervous systems 10.5
22 mycosis fungoides 10.5
23 diffuse large b-cell lymphoma 10.5
24 erdheim-chester disease 10.5
25 follicular lymphoma 10.5
26 acute leukemia 10.4 FLT3 KMT2A MLLT10
27 febrile seizures, familial, 2 10.4 CSF2 CSF3 IL3
28 von hippel anomaly 10.4 IL3 JAK2 RUNX1
29 mental retardation, autosomal dominant 37 10.4 CSF2 CSF3 IL3
30 eosinophilic cystitis 10.4 ABCB1 CSF2 CSF3
31 neutrophilia, hereditary 10.4 CSF2 FLT3 PTHLH
32 colorectal adenoma 10.4 ETV6 FLT3 JAK2 RUNX1
33 sarcoma 10.4 CSF2 IL2 KIT
34 scleroderma, familial progressive 10.4 CSF2 CSF3 IL3
35 rnase t2-deficient leukoencephalopathy 10.4 ETV6 KMT2A
36 kahrizi syndrome 10.4 IL3 KIT WT1
37 grix blankenship peterson syndrome 10.4 CSF2 CSF3 IL3
38 diffuse glomerulonephritis 10.4 ETV6 KIT WT1
39 dupuytren contracture 10.4 FLT3 KIT RUNX1
40 unilateral hemispheric polymicrogyria 10.4 FLT3 KIT RUNX1 RUNX1T1
41 lymphomatoid granulomatosis 10.4 ETV6 KMT2A RUNX1 RUNX1T1
42 acute respiratory distress syndrome 10.4 FLT3 JAK2 KIT NPM1
43 acute zonal occult outer retinopathy 10.4 FLT3 NPM1
44 extranodal nasal nk/t cell lymphoma 10.4 CDKN2B CSF3 KIT
45 malignant testicular leydig cell tumor 10.4 FLT3 NPM1 RUNX1
46 sinusitis 10.4 CSF2 CSF3 IL3 JAK2
47 glycogen storage disease type 0 10.4 FLT3 KMT2A NPM1 WT1
48 adult respiratory distress syndrome 10.4 FLT3 KMT2A MLLT10 NUP98
49 dic in newborn 10.4 CSF2 CSF3 IL3
50 neurofibromatosis 10.4 FLT3 KIT KMT2A NPM1

Graphical network of the top 20 diseases related to Hematologic Cancer:



Diseases related to Hematologic Cancer

Symptoms & Phenotypes for Hematologic Cancer

GenomeRNAi Phenotypes related to Hematologic Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.1 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.1 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.1 ABL1 FLT3 KIT

MGI Mouse Phenotypes related to Hematologic Cancer:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.44 ABCB1 ABL1 CDKN2B CSF2 CSF3 ENG
2 growth/size/body region MP:0005378 10.43 JAK2 KIT KMT2A NPM1 NUP98 ABCB1
3 cardiovascular system MP:0005385 10.39 ABCB1 ABL1 CSF2 ENG ETV6 IL2
4 cellular MP:0005384 10.38 ABL1 CDKN2B CSF2 ETV6 FLT3 IL2
5 immune system MP:0005387 10.38 ETV6 FLT3 IL2 JAK2 KIT KMT2A
6 homeostasis/metabolism MP:0005376 10.34 IL2 JAK2 KIT KMT2A ABCB1 ABL1
7 mortality/aging MP:0010768 10.33 ABCB1 ABL1 CDKN2B CSF2 ENG ETV6
8 endocrine/exocrine gland MP:0005379 10.31 FLT3 IL2 JAK2 KIT PTHLH ABCB1
9 embryo MP:0005380 10.29 ABL1 CSF2 ENG ETV6 JAK2 KIT
10 integument MP:0010771 10.23 CSF3 ENG ETV6 JAK2 KIT KMT2A
11 digestive/alimentary MP:0005381 10.16 ETV6 IL2 KIT PTHLH RUNX1T1 ABCB1
12 neoplasm MP:0002006 10.11 CDKN2B CSF2 ETV6 FLT3 IL2 JAK2
13 liver/biliary system MP:0005370 10.09 ABCB1 ABL1 IL2 JAK2 KIT KMT2A
14 no phenotypic analysis MP:0003012 10.02 ABCB1 CDKN2B ETV6 FLT3 IL2 KIT
15 normal MP:0002873 9.91 ABL1 ENG ETV6 JAK2 KIT KMT2A
16 renal/urinary system MP:0005367 9.7 CDKN2B CSF2 CSF3 KIT KMT2A PTHLH
17 reproductive system MP:0005389 9.65 ABCB1 CDKN2B CSF2 IL2 JAK2 KIT
18 respiratory system MP:0005388 9.23 ABL1 CSF2 ENG IL2 KIT PTHLH

Drugs & Therapeutics for Hematologic Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Adcetris 17 46 BRENTUXIMAB VEDOTIN Seattle Genetics Approved August 2011
2
Arranon 17 46 NELARABINE GlaxoSmithKline Approved October 2005
3
Zydelig 17 46 IDELALISIB Gilead Approved July 2014

Drugs for Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1070)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1 9041-08-1
4
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
5
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
7
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53910-25-1 40926 439693
8
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
9
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
10
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
11
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
12
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
14
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
15
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
16
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
17
Asparaginase Approved Phase 4,Phase 2,Phase 3,Phase 1 9015-68-3
18
Pegaspargase Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 130167-69-0
19
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
20
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 23214-92-8 31703
21
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
22
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
23
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
24
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
25
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
26
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 56420-45-2 41867
27
Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 52-24-4 5453
28
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
29
Darbepoetin alfa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11096-26-7, 209810-58-2
30
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1 90357-06-5 56069 2375
31
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
32
Panobinostat Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 404950-80-7 6918837
33
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 55-98-1 2478
34
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
35
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1 33419-42-0 36462
36
Azacitidine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 320-67-2 9444
37
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 120511-73-1 2187
38
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1 1959-05-2, 59-05-2 126941
39
Ciprofloxacin Approved, Investigational Phase 4,Phase 3 85721-33-1 2764
40
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
41
Bleomycin Approved Phase 4,Phase 2,Phase 3,Phase 1 11056-06-7 5360373
42
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
43
Menthol Approved Phase 4,Phase 2,Phase 1 2216-51-5 16666
44
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 85622-93-1 5394
45
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-75-2 4033
46
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
47
Arsenic trioxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1327-53-3 518740
48
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
49
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
50
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show top 50) (show all 5127)
id Name Status NCT ID Phase
1 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4
2 Intrabone Cord Blood Transplantation Unknown status NCT00838019 Phase 4
3 Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis Unknown status NCT00450645 Phase 4
4 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4
5 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4
6 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4
7 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4
8 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4
9 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
10 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4
11 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4
12 Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy Unknown status NCT01571518 Phase 4
13 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4
14 A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation Completed NCT00067730 Phase 4
15 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
16 The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants Completed NCT01021683 Phase 4
17 VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands Completed NCT00440765 Phase 4
18 ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Completed NCT00440479 Phase 4
19 Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients Completed NCT01060462 Phase 4
20 A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies Completed NCT02564094 Phase 4
21 Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units Completed NCT00167999 Phase 4
22 Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia Completed NCT00315484 Phase 4
23 Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Completed NCT00590213 Phase 4
24 Non-invasive Ventilation in Terminally Ill Cancer Patients Completed NCT00533143 Phase 4
25 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area Completed NCT02372357 Phase 4
26 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4
27 Thai Cancer Anemia Survey in Chulalongkorn Hospital Completed NCT01018043 Phase 4
28 National Cancer Institute Thai Cancer Anemia Survey Completed NCT01030159 Phase 4
29 Early Application of CPAP in Hematologic Completed NCT00507533 Phase 4
30 Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients Completed NCT02108444 Phase 4
31 Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters Completed NCT00994136 Phase 4
32 A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy Completed NCT00216541 Phase 4
33 A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy Completed NCT00283465 Phase 4
34 A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia Completed NCT01394991 Phase 4
35 Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia Completed NCT00264108 Phase 4
36 A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia Completed NCT00117039 Phase 4
37 Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer Completed NCT01989845 Phase 4
38 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
39 Pilot Study: Hepatoprotective Role of SMOFlipid® Used in Short-term Parenteral Nutrition in an Onco-Hematology Pediatric Population Completed NCT02539316 Phase 4
40 Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy Completed NCT00224068 Phase 4
41 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4
42 A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors Completed NCT02554942 Phase 4
43 Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2) Completed NCT00398749 Phase 4
44 Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients Completed NCT01129336 Phase 4
45 Oral Zinc Therapy for the Prevention of Mucositis Completed NCT00449592 Phase 4
46 Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia Completed NCT00212862 Phase 4
47 Guilford Genomic Medicine Initiative (GGMI) Completed NCT01372553 Phase 4
48 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4
49 Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia Completed NCT01374373 Phase 4
50 A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen Completed NCT01107756 Phase 4

Search NIH Clinical Center for Hematologic Cancer

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hematologic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hematologic Cancer:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Allocord, cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Co-infusion of umbilical cord blood and haploidentical CD34+ cells for hematological diseases
Ducord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Expanded cord blood hematopoietic stem cells for hematologic malignancies
Hemacord
Hematopoietic stem cells for treatment of hematologic malignancies
StemEx
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Hematologic Cancer:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905
Umbilical cord blood-derived hematopoietic progenitor cells (Allocord) PMIDs: 11953027
Peripheral blood-derived hematopoietic stem cells
Umbilical cord blood-derived hematopoietic progenitor cells (Ducord) PMIDs: 22698485 21810098 23711284 21277377
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 21396596
Expanded umbilical cord blood-derived hematopoietic stem cells PMIDs: 21396596
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 20676147

Cochrane evidence based reviews: hematologic neoplasms

Genetic Tests for Hematologic Cancer

Genetic tests related to Hematologic Cancer:

id Genetic test Affiliating Genes
1 Hematologic Neoplasm 29

Anatomical Context for Hematologic Cancer

MalaCards organs/tissues related to Hematologic Cancer:

39
Bone, Lymph Node, Bone Marrow, B Cells, T Cells, Testes, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Hematologic Cancer:

18
The Hematological System

Publications for Hematologic Cancer

Articles related to Hematologic Cancer:

(show all 46)
id Title Authors Year
1
Mosaic 13q14 deletions in peripheral leukocytes of non-hematologic cancer cases and healthy controls. ( 26763882 )
2016
2
Associations between dyadic coping and supportive care needs: findings from a study with hematologic cancer patients and their partners. ( 27987096 )
2016
3
Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer. ( 27400009 )
2016
4
Understanding strength exercise intentions and behavior in hematologic cancer survivors: an analysis of the intention-behavior gap. ( 27052642 )
2016
5
Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely? ( 27282880 )
2016
6
Cancer Care Burden among Primary Family Caregivers of Iranian Hematologic Cancer Patients. ( 26225701 )
2015
7
Cost Analysis of Voriconazole Versus Liposomal Amphotericin B for Primary Therapy of Invasive Aspergillosis among High-Risk Hematologic Cancer Patients in Brazil. ( 26534377 )
2015
8
Hospitalization risk according to geriatric assessment and laboratory parameters in elderly hematologic cancer patients. ( 25684525 )
2015
9
Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. ( 26310541 )
2015
10
Survivorship Care Plans and Treatment Summaries a8"in Adult Patients With Hematologic Cancer: a8"An Integrative Literature Review. ( 25901380 )
2015
11
Cost Analysis of Voriconazole Versus Liposomal Amphotericin B And Caspofungin for Primary Therapy of Invasive Aspergillosis Among High-Risk Hematologic Cancer Patients In Saudi Arabia. ( 26533739 )
2015
12
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. ( 24813251 )
2014
13
The microfluidic multitrap nanophysiometer for hematologic cancer cell characterization reveals temporal sensitivity of the calcein-AM efflux assay. ( 24873950 )
2014
14
Combination of vaccine-strain measles and mumps virus synergistically kills a wide range of human hematological cancer cells: Special focus on acute myeloid leukemia. ( 25193462 )
2014
15
Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. ( 24645687 )
2014
16
The falling incidence of hematologic cancer after heart transplantation. ( 25100534 )
2014
17
Confirmation of the reported association of clonal chromosomal mosaicism with an increased risk of incident hematologic cancer. ( 23533652 )
2013
18
Internet-based program for coping with cancer: a randomized controlled trial with hematologic cancer patients. ( 22565413 )
2013
19
Evaluation of MycAssaya8c Aspergillus for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer. ( 23620764 )
2013
20
Xist RNA is a potent suppressor of hematologic cancer in mice. ( 23415223 )
2013
21
p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. ( 23029260 )
2012
22
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study. ( 22099500 )
2012
23
Thymidylate synthase polymorphisms and hematological cancer risk: a meta-analysis. ( 22166040 )
2012
24
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. ( 22622039 )
2012
25
Physical activity and hematologic cancer prevention. ( 21113763 )
2011
26
Improving access to information and support for patients with less common cancers: hematologic cancer patients' views about Web-based approaches. ( 22189354 )
2011
27
Evolving information priorities of hematologic cancer survivors, caregivers, and other relatives. ( 20119694 )
2010
28
Mesial temporal sclerosis as a complication of hematologic cancer. ( 19434437 )
2009
29
Femoral resurfacing in young patients with hematologic cancer and osteonecrosis. ( 18679763 )
2008
30
Managed care considerations: hematologic cancer as a chronic disease. ( 19119536 )
2008
31
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. ( 18344563 )
2008
32
Phase 3 trials suggest ways to improve current hematologic cancer therapies. ( 18252877 )
2008
33
The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. ( 17683622 )
2007
34
Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy. ( 17516403 )
2007
35
Posaconazole prophylaxis in hematologic cancer. ( 17526089 )
2007
36
Posaconazole prophylaxis in hematologic cancer. ( 17526091 )
2007
37
Posaconazole prophylaxis in hematologic cancer. ( 17522407 )
2007
38
Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. ( 17607669 )
2007
39
Posaconazole prophylaxis in hematologic cancer. ( 17526090 )
2007
40
Patient-rated emotional and physical functioning among hematologic cancer patients during hospitalization for stem-cell transplantation. ( 15580279 )
2005
41
In vitro chemosensitivity testing of hematological cancer patients: detection of ornithine decarboxylase. ( 12528799 )
2003
42
Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. ( 11919251 )
2002
43
In vitro chemosensitivity testing of hematological cancers: immunohistochemical detection of ornithine decarboxylase. ( 10587289 )
1999
44
Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. ( 8358720 )
1993
45
Autologous bone marrow transplantation for hematologic cancer. ( 2236163 )
1990
46
Alzheimer's disease and senile dementia: genetic relationships to Down's syndrome and hematologic cancer. ( 154163 )
1979

Variations for Hematologic Cancer

ClinVar genetic disease variations for Hematologic Cancer:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CBL NM_005188.3(CBL): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic/Likely pathogenic rs267606706 GRCh37 Chromosome 11, 119148891: 119148891
2 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913507 GRCh37 Chromosome 4, 55599321: 55599321
3 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
4 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
5 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh37 Chromosome 4, 55594221: 55594221
6 MPL NM_005373.2(MPL): c.1544G> T (p.Trp515Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913615 GRCh37 Chromosome 1, 43815009: 43815009
7 CBL NM_005188.3(CBL): c.1150T> C (p.Cys384Arg) single nucleotide variant Pathogenic/Likely pathogenic rs387906664 GRCh37 Chromosome 11, 119148930: 119148930
8 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh38 Chromosome 12, 11869601: 11869601
9 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh38 Chromosome 12, 11884541: 11884541
10 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh37 Chromosome 12, 12038902: 12038902

Expression for Hematologic Cancer

Search GEO for disease gene expression data for Hematologic Cancer.

Pathways for Hematologic Cancer

Pathways related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.21 CSF2 CSF3 FLT3 IL2 IL3 JAK2
2 12.55 ABL1 CDKN2B FLT3 KIT RUNX1 RUNX1T1
3 12.46 CSF3 IL2 IL3 JAK2 KIT
4 12.38 IL2 IL3 JAK2 KIT RUNX1 RUNX1T1
5
Show member pathways
12.24 FLT3 KIT RUNX1 RUNX1T1
6
Show member pathways
12.07 CSF2 CSF3 IL2 IL3 JAK2
7
Show member pathways
12 CSF2 IL2 IL3 JAK2
8 11.92 ABL1 FLT3 JAK2 KIT NPM1
9
Show member pathways
11.75 CSF2 CSF3 JAK2
10 11.68 IL2 KIT RUNX1
11
Show member pathways
11.65 CSF2 IL2 IL3
12 11.64 CSF2 FLT3 IL2 KIT
13 11.64 CSF2 CSF3 FLT3 IL3 KIT
14
Show member pathways
11.6 ABCB1 ABL1 KIT
15 11.57 IL2 IL3 JAK2
16 11.57 CSF2 CSF3 ENG FLT3 IL2 IL3
17 11.55 ABL1 IL2 WT1
18 11.54 ABCB1 ENG NPM1
19 11.48 CSF2 ETV6 FLT3 IL3 KMT2A RUNX1
20 11.3 CSF2 CSF3 IL3 RUNX1
21 11.07 CSF2 CSF3 IL2 IL3
22 10.93 CSF2 CSF3 IL2 IL3

GO Terms for Hematologic Cancer

Cellular components related to Hematologic Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.32 ABL1 JAK2 KMT2A MLLT10 NPM1 NUP98

Biological processes related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.96 CDKN2B CSF3 ENG ETV6 IL2 KMT2A
2 negative regulation of cell proliferation GO:0008285 9.95 CDKN2B JAK2 KMT2A NPM1 PTHLH WT1
3 MAPK cascade GO:0000165 9.91 CSF2 IL2 IL3 JAK2 KIT
4 regulation of cell proliferation GO:0042127 9.87 ABL1 CSF2 JAK2 KIT
5 protein autophosphorylation GO:0046777 9.85 ABL1 FLT3 JAK2 KIT
6 positive regulation of cell proliferation GO:0008284 9.81 CSF2 CSF3 FLT3 IL2 IL3 JAK2
7 peptidyl-tyrosine phosphorylation GO:0018108 9.8 ABL1 CSF2 FLT3 IL3 JAK2 KIT
8 cytokine-mediated signaling pathway GO:0019221 9.77 CSF3 FLT3 IL3 JAK2 KIT
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.76 ABL1 CSF3 IL3 JAK2
10 hemopoiesis GO:0030097 9.75 FLT3 KIT RUNX1
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 CSF3 FLT3 JAK2 KIT
12 spleen development GO:0048536 9.7 ABL1 CDKN2B KMT2A
13 embryonic hemopoiesis GO:0035162 9.61 IL3 KIT KMT2A
14 negative regulation of cell-cell adhesion GO:0022408 9.6 ABL1 JAK2
15 hematopoietic stem cell proliferation GO:0071425 9.59 ETV6 RUNX1
16 dendritic cell differentiation GO:0097028 9.58 CSF2 FLT3
17 negative regulation of heart contraction GO:0045822 9.56 IL2 JAK2
18 myeloid progenitor cell differentiation GO:0002318 9.54 FLT3 KIT
19 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.49 ENG KIT
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.43 CSF2 FLT3 IL2 IL3 JAK2 KIT
21 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.02 CSF2 IL2 IL3 JAK2 KIT

Molecular functions related to Hematologic Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 CSF2 CSF3 IL2 IL3
2 growth factor activity GO:0008083 9.46 CSF2 CSF3 IL2 IL3
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.35 CSF2 IL2 IL3 JAK2 KIT
4 peptide hormone receptor binding GO:0051428 9.32 JAK2 PTHLH
5 protein tyrosine kinase activity GO:0004713 9.1 ABL1 CSF2 FLT3 IL3 JAK2 KIT

Sources for Hematologic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....